Wandercraft Timeline

Events

• 2026-07-27 - Regulatory - Ecuador authorises Wandercraft Atalante X for clinical rehabilitation - The authorised uses cover rehabilitation associated with spinal-cord injury, stroke-related hemiplegia and multiple sclerosis. Clínica de Lesiones Deportivas in Quito is the first announced Ecuador installation site. The clinic describes Atalante X as… - source: clinicadelesionesdeportivas.com
• 2026-03-12 - Deployment - Renault Group deploys 350 Wandercraft Calvin-40 humanoid robots - • Renault Group deployed 350 Wandercraft Calvin-40 humanoid robots in its factories over an 18-month period. • The robots performed physically demanding tasks, such as hauling tires, at the Douai factory's supply line. • This deployment followed a strategic… - source: autoexpress.co.uk
• 2025-11-12 - Deployment - SAPA announces planned deployment of Wandercraft Calvin-40 humanoids - SAPA and Wandercraft will implement and scale Calvin-40, Wandercraft's autonomous heavy-payload modular humanoid, in SAPA industrial operations. The first implementation phase will focus on precise, repetitive movement of large and heavy parts in… - source: wandercraft.eu
• 2025-08-01 - Research Publication - Atalante X powered exoskeleton highlighted in rehabilitation study - The publication is an exact Atalante X powered-exoskeleton research record. The record adds product-specific clinical and rehabilitation context for Wandercraft’s self-balancing exoskeleton line. The source is bound only to Atalante X because the title names… - source: doi.org
• 2025-06-11 - Market Signal - Wandercraft secures $75M mixed equity-and-debt Series D package - Renault Group, the France 2030 PSIM fund managed by Bpifrance, Teampact Ventures and Quadrant Management made major contributions. The package combined equity and debt rather than representing a pure private-equity round. Wandercraft tied the capital to Eve… - source: wandercraft.eu
• 2025-06-11 - Funding - Wandercraft secures €64.3 million in Series D funding - • Wandercraft secured €64.3 million in a Series D funding round on June 11, 2025. • Investors included Renault Group, Bpifrance, the European Investment Bank, Teampact Ventures, and others. • The funding will support the commercialization of their personal… - source: eu-startups.com
• 2024-02-13 - Regulatory - Wandercraft's Atalante X receives second FDA clearance - • Wandercraft received FDA clearance for Atalante X for rehabilitation in individuals with spinal cord injuries at levels T5 to L5. • This follows the device's previous clearance for stroke rehabilitation in December 2022. • The clearance is supported by… - source: wandercraft.eu
• 2023-12-28 - Market Signal - Wandercraft receives EUR 25M EIB loan - The EIB loan supports development of Wandercraft's personal exoskeleton and access to Atalante X. The financing benefits from an InvestEU guarantee. The transaction is debt financing rather than a private-equity round. - source: eib.org